BTIG Maintains Buy Rating on Jade Biosciences at $28 Target
ArchivedSingle Source|2 articles|1 sources|1 blocks
Detected: Updated: Analyzed:
NarrativeRadar Analysis·Reviewed by
Reported Facts
Observable data points shared across all narratives
- •BTIG issued the latest Buy rating on March 6, 2026.
- •The price target for Jade Biosciences stock remains at $28.
- •BTIG also reiterated a Buy rating on Praxis Precision Medicines stock at $843 on March 9, 2026.
What Could Happen If...
- ▸Jade Biosciences reports strong quarterly earnings investor confidence could increase, potentially driving the stock price above the $28 target
Market Exposure
StocksJade BiosciencesUpward Pressure
BTIG's maintained Buy rating and price target support positive investor sentiment toward Jade Biosciences shares.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Instruments
Organizations
Source Coverage
FINANCE
2 articles
More coverage on this story
- More on Jade Biosciences stock
- More on BTIG
- More on Jade Biosciences
Signals
Single-block coverage
Related Events
▸BTIG maintains Sophia Genetics rating citing customer growthArchived▸BTIG maintains Buy rating on ImmunityBio after FDA warningArchived▸Jones Trading Reiterates Buy on TriSalus Life Sciences StockArchived▸Lattice Semiconductor stock price target raised to $110 from $80 at StifelArchived▸Truist Reiterates Buy on Legend Biotech with $70 Price Target